Thus, the restoration of MEK1/2/ERK1/2 and inhibition of AP-1 activity by SAMC seem to be one of the important effects of SAMC when exerting its hepato-protective function during NAFLD. This evidence concerns the gene MAP2K1 and metabolic dysfunction-associated steatotic liver disease.